CalciMedica/$CALC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CalciMedica
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
- Ticker
- $CALC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- La Jolla, United States
- Website
- calcimedica.com
CalciMedica Metrics
BasicAdvanced
$8.5M
-
-$3.55
-
-
Price and volume
Market cap
$8.5M
52-week high
$2.47
52-week low
$1.00
Average daily volume
77K
Financial strength
Current ratio
4.959
Quick ratio
4.802
Long term debt to equity
1.632
Total debt to equity
1.632
Interest coverage (TTM)
-14.15%
Profitability
EBITDA (TTM)
-18.733
Management effectiveness
Return on assets (TTM)
-80.28%
Return on equity (TTM)
-763.32%
Valuation
Price to book
2.02
Price to tangible book (TTM)
2.02
Growth
Earnings per share change (TTM)
-55.95%
3-year earnings per share growth (CAGR)
-58.30%
What the Analysts think about CalciMedica
Analyst ratings (Buy, Hold, Sell) for CalciMedica stock.
Analyst projections of the future price of CalciMedica stock.
CalciMedica Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.